Status: Not yet recruiting
Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
This is an open-label randomized controlled trial to evaluate the efficacy and safety of one dose versus two doses of ripertamab in children with frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS).
Participants needed: 312
Trial details
Age: 1-16Biological sex: AllType: InterventionalSponsor: Mao JianhuaUpdated: Feb 5, 2026Locations: 1
Eligibility criteria
16 years old and above with FRNS/SDNS [+4]
Known causes (such as systemic lupus erythematosus, IgA nephropathy, other secon... [+5]